shares drug suspension
shares elan biogen idec plunged suspended multiple sclerosis drug tysabri patient death
york stock exchange shares elan partner biogen idec death central nervous disease suspected condition cited tysabri avonex biogen idec existing multiple sclerosis drug rare condition progressive multifocal leukoencephalopathy pml patients tysabri avonex tysabri approved tipped leading multiple sclerosis treatment
clinical investigators evaluate patients consult leading experts understand pml outcome evaluations determine dosing clinical trials commercial availability
biogen idec faced rivals avonex elan irish stock exchange receive boost inquiry elan accounts bankruptcy rebuilding increasing tysabri ian hunter goodbody stockbrokers dublin mark elan finished biogen fell
shares pharmaceutical phytopharm closed pence stock exchange partner pull experimental alzheimer disease treatment phytopharm yamanouchi pharmaceutical licensing agreement prompting reserves
